腹部大手术后(1→3)-β-D-葡聚糖作为预后标志物的研究
基于INTENSE研究数据的事后分析,评估腹部大手术后血清BDG水平与器官衰竭及死亡的关系,并校正侵袭性念珠菌病和抗真菌治疗的影响。结果显示BDG>100 pg/mL与SOFA评分升高及死亡率增加显著相关,且持续或升高BDG提示不良预后,与是否合并侵袭性念珠菌病无关。
要点
- 腹部大手术后BDG>100 pg/mL与SOFA评分升高及死亡率增加相关。
- 多次BDG>100 pg/mL或BDG持续升高者死亡率更高。
- BDG的不良预后关联不受侵袭性念珠菌病或米卡芬净使用影响。
核心结论
- 腹部大手术后循环中持续存在或升高的BDG与显著增高的并发症率和死亡率相关,且不依赖于侵袭性念珠菌病。
研究设计与样本
- 基于INTENSE研究(预防性使用米卡芬净预防腹部手术后侵袭性念珠菌病)数据的事后分析,测定血清BDG负荷以辅助诊断侵袭性念珠菌病。
主要发现
- BDG>100 pg/mL者SOFA评分显著高于≤100 pg/mL者(2 vs 5,P < .0001)。
- BDG>100 pg/mL者死亡率显著高于≤100 pg/mL者(39.0% vs 13.7%,P = .0002)。
- 多次(≥2次)BDG>100 pg/mL或BDG升高>100 pg/mL者死亡率为48.1%。
- 合并侵袭性念珠菌病者中,BDG>100 pg/mL与≤100 pg/mL的死亡率分别为42.3%和25.0%。
- 无侵袭性念珠菌病但BDG>100 pg/mL者死亡率为37.3%。
关键数值与推荐
- BDG浓度阈值100 pg/mL用于分组分析。
- 多次(≥2次)阳性>100 pg/mL或BDG浓度升高>100 pg/mL定义为持续或升高BDG。
临床怎么用
- 腹部大手术后监测BDG>100 pg/mL或持续升高可提示不良预后,即使无侵袭性念珠菌病证据也应关注器官衰竭和死亡风险。
- 米卡芬净预防性使用不改变BDG与不良预后的关联,临床解读BDG时应考虑宿主因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While the serological detection of (1→3)-β-D-glucan (BDG) can indicate invasive fungal disease (IFD), false positivity occurs. Nevertheless, the presence of BDG can still be recognized by the host's innate immune system and persistent BDG antigenemia, in the absence of IFD, can result in deleterious proinflammatory immune responses. METHODS: During the XXX (INTENSE) study into the preemptive use of micafungin to prevent invasive candidiasis (IC) after abdominal surgery, the serum burden of BDG was determined to aid diagnosis of IC. Data from the INTENSE study were analyzed to determine whether BDG was associated with organ failure and patient mortality, while accounting for the influences of IC and antifungal therapy. RESULTS: A BDG concentration >100 pg/mL was associated with a significantly increased Sequential Organ Failure Assessment score (≤100 pg/mL: 2 vs >100 pg/mL: 5; P < .0001) and increased rates of mortality (≤100 pg/mL: 13.7% vs >100 pg/mL: 39.0%; P = .0002). Multiple (≥2) positive results >100 pg/mL or a BDG concentration increasing >100 pg/mL increased mortality (48.1%). The mortality rate in patients with IC and a BDG concentration >100 pg/mL and ≤100 pg/mL was 42.3% and 25.0%, respectively. The mortality rate in patients without IC but a BDG concentration >100 pg/mL was 37.3%. The use of micafungin did not affect the findings. CONCLUSIONS: The presence of persistent or increasing BDG in the patient's circulation is associated with significant morbidity and mortality after abdominal surgery, irrespective of IC. The potential lack of a specific therapeutic focus has consequences when trying to manage these patients, and when designing clinical trials involving patients where host-associated BDG concentrations may be elevated. CLINICAL TRIALS REGISTRATION: NCT01122368.
引用
- White PL, Posso R, Parr C, et al. The Presence of (1→3)-β-D-Glucan as Prognostic Marker in Patients After Major Abdominal Surgery. Clin Infect Dis. 2021. PMID: 32914187. doi:10.1093/cid/ciaa1370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。